A novel nerve stimulation treatment has demonstrated significant long-term benefits for individuals suffering from severe and treatment-resistant depression (TRD), according to findings from a recent study. The treatment involves stimulating the vagus nerve, a major nerve connecting the brainstem to the abdomen, using an implanted device similar to a pacemaker.
Durable Improvement in Depression Symptoms
The two-year study, a follow-up phase of the RECOVER trial, revealed that 69 percent of patients experienced a meaningful improvement in their depressive symptoms. Crucially, for over 80 percent of these patients, the benefit was sustained through the second year of treatment. Researchers defined meaningful improvement as at least a 30 percent reduction in symptoms or measurable enhancements in daily functioning. Furthermore, by the end of the two-year period, more than 20 percent of patients achieved remission, indicating a return to normal functioning.
About 2.8 million to 7 million adults in the U.S. live with TRD, a condition where individuals have not found relief despite trying at least two antidepressants at appropriate doses and durations. The study focused on patients with particularly severe cases; on average, participants had been experiencing depression for 17 years and had previously failed more than 13 different treatments, including medications, therapy, and electroconvulsive therapy.
How Vagus Nerve Stimulation Works
The vagus nerve plays a critical role in regulating mood, stress, and emotional control by transmitting signals between the brain and major organs. The VNS device, surgically implanted below the collarbone, sends low-level electrical pulses to the left vagus nerve. These pulses travel to the brainstem and affect brain regions involved in mood and emotion. The implant is designed for long-term use, with battery life ranging from two to 16 years depending on the device.
The study assessed improvements using standard questionnaires measuring depressive symptoms, daily functioning, and quality of life. Researchers ensured that the observed benefits were not due to patients concurrently increasing medication or seeking other therapies, finding no significant changes in such treatments during the second year of the study. The findings suggest that VNS may take time to exert its full effect, as approximately 30 to 38 percent of patients who had not improved after 12 months went on to experience benefits in the second year.
Addressing a Dire Need
"There is a dire need to find effective treatments for these patients, who often have no other options," said Dr. Charles Conway, lead author of the study and director of Washington University's Treatment Resistant Mood Disorders Center. "We were shocked that one in five patients was effectively without depressive symptoms at the end of two years."
This research was funded by LivaNova PLC, the manufacturer of the VNS device. The company supported the study's conduct, data analysis, and report drafting, and several authors have financial ties to the company. Authors stated that they independently approved the final manuscript.
Traditional treatments for depression, such as SSRIs, are effective for many but can cause side effects like weight gain, sexual dysfunction, and emotional blunting. For a significant portion of the population, these medications are insufficient, highlighting the importance of exploring alternative therapeutic approaches like vagus nerve stimulation.